Ropeginterferon alfa-2b (Besremi®). HTA ID: 23004

Assessment Status NCPE assessment ongoing
HTA ID 23004
Drug Ropeginterferon alfa-2b
Brand Besremi®
Indication Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
Assessment Process
Rapid review commissioned 20/01/2023
Rapid review completed 15/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/03/2023
Pre-submission consultation with Applicant 03/05/2023
Full submission received from Applicant 20/07/2023
Preliminary review sent to Applicant 27/11/2023
NCPE assessment re-commenced 03/01/2024
Factual accuracy sent to Applicant 26/06/2024
NCPE assessment re-commenced 15/07/2024